Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
J Antimicrob Chemother. 2018 Jun 1;73(6):1651-1658. doi: 10.1093/jac/dky030.
Micafungin has a distinct advantage for antifungal prophylaxis in HSCT owing to its better safety profile, specifically in terms of hepatic and renal toxicity. In children, prophylactic micafungin is given as either 1 mg/kg every day or 3 mg/kg every other day.
We performed a prospective single-centre observational study that investigated the pharmacokinetics (PK) of a single 5 mg/kg dose of micafungin in young children undergoing HSCT, to ascertain the eventual feasibility of twice-weekly prophylactic administration.
Nine children, ≤10 years of age undergoing HSCT, were enrolled and received a single intravenous dose of 5 mg/kg micafungin. Blood samples were obtained for PK analysis. Micafungin plasma concentration of >0.2 mg/L was chosen for target attainment (i.e. considered adequate prophylactic concentration). In addition, a population PK model was developed based on current and our previous PK study data. We also evaluated PK model-based simulation of PK profiles and target attainment using Monte Carlo simulation, for several dosing scenarios.
Mean clearance was 15.3 mL/h/kg (range 11.0-21.4 mL/h/kg) and the mean elimination half-life was 11.6 h (range 7.8-16.6 h). The mean concentration at 96 h was 0.11 mg/L (range 0.03-0.26 mg/L). Eleven percent (n = 1) of patients achieved target attainment at the end of 96 h. Simulation data showed that 1 mg/kg daily dosing and 3 mg/kg alternate-day dosing strategies achieved at least 99% and 81% target attainment, respectively, whereas a 5 mg/kg with 3 day-interval dosing strategy resulted in 64%, 72% and 84% target attainments in patients with body weights of 10, 20 and 30 kg, respectively.
Micafungin at 5 mg/kg dosing did not achieve target attainment at the end of 96 h for antifungal prophylaxis in children undergoing HSCT. Simulation data suggest that a dosing strategy of micafungin at 5 mg/kg every 72 h is more likely to achieve target attainment in children with a higher body weight in comparison with children with a lower body weight. A cautious approach is advisable when using a high, but less frequent, dosing strategy in very young children.
米卡芬净在 HSCT 中的抗真菌预防具有明显优势,因为它具有更好的安全性,特别是在肝毒性和肾毒性方面。在儿童中,预防性米卡芬净的给药剂量为 1mg/kg 每天或 3mg/kg 每隔一天。
我们进行了一项前瞻性单中心观察性研究,旨在研究接受 HSCT 的年轻儿童单次给予 5mg/kg 剂量的米卡芬净的药代动力学(PK),以确定每周两次预防性给药的可行性。
9 名年龄≤10 岁接受 HSCT 的儿童接受了单次静脉注射 5mg/kg 米卡芬净。采集血样进行 PK 分析。选择米卡芬净血浆浓度>0.2mg/L 作为目标达到(即认为是足够的预防性浓度)。此外,根据当前和我们之前的 PK 研究数据,建立了一个群体 PK 模型。我们还使用蒙特卡罗模拟对几种给药方案进行了基于 PK 模型的 PK 曲线和目标达到的模拟。
平均清除率为 15.3mL/h/kg(范围为 11.0-21.4mL/h/kg),平均消除半衰期为 11.6h(范围为 7.8-16.6h)。96 小时时的平均浓度为 0.11mg/L(范围为 0.03-0.26mg/L)。11%(n=1)的患者在 96 小时时达到目标浓度。模拟数据显示,1mg/kg 每日剂量和 3mg/kg 隔日剂量策略的目标达到率分别至少为 99%和 81%,而 5mg/kg 每 3 天给药策略在体重为 10、20 和 30kg 的患者中分别导致 64%、72%和 84%的目标达到率。
对于接受 HSCT 的儿童,5mg/kg 剂量的米卡芬净在 96 小时时未达到预防真菌感染的目标浓度。模拟数据表明,与体重较低的儿童相比,5mg/kg 米卡芬净每 72 小时的给药策略更有可能在体重较高的儿童中达到目标浓度。在非常年幼的儿童中使用高但频率较低的给药策略时应谨慎。